Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Research & Development (2016 - 2025)

Arrowhead Pharmaceuticals' Research & Development history spans 16 years, with the latest figure at $177.2 million for Q4 2025.

  • For Q4 2025, Research & Development rose 29.34% year-over-year to $177.2 million; the TTM value through Dec 2025 reached $647.4 million, up 22.98%, while the annual FY2025 figure was $607.2 million, 20.02% up from the prior year.
  • Research & Development reached $177.2 million in Q4 2025 per ARWR's latest filing, up from $174.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $177.2 million in Q4 2025 to a low of $44.7 million in Q1 2021.
  • Average Research & Development over 5 years is $105.5 million, with a median of $97.3 million recorded in 2023.
  • Peak YoY movement for Research & Development: skyrocketed 82.13% in 2021, then decreased 1.45% in 2023.
  • A 5-year view of Research & Development shows it stood at $65.8 million in 2021, then grew by 27.26% to $83.7 million in 2022, then soared by 39.19% to $116.5 million in 2023, then grew by 17.61% to $137.0 million in 2024, then rose by 29.34% to $177.2 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Research & Development are $177.2 million (Q4 2025), $174.7 million (Q3 2025), and $162.4 million (Q2 2025).